Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

518.53
+5.651.10%
Post-market: 517.96-0.5700-0.11%17:43 EDT
Volume:876.49K
Turnover:454.36M
Market Cap:22.24B
PE:18.55
High:520.66
Open:516.07
Low:515.54
Close:512.88
52wk High:609.35
52wk Low:302.19
Shares:42.89M
Float Shares:39.35M
Volume Ratio:2.22
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.47
PE(LYR):18.61

Loading ...

United Therapeutics Chairperson and CEO Martine A. Rothblatt Reports Disposal of Common Shares Worth $5,031,247.39

Reuters
·
Yesterday

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and AdaptHealth (AHCO)

TIPRANKS
·
Aug 24

United Therapeutics Says FDA Accepts Ralinepag NDA for Pulmonary Arterial Hypertension

Reuters
·
Aug 24

United Therapeutics Corporation: Ralinepag Has not Been Approved for Use in Any Indication by FDA and Remains Investigational for Pah

THOMSON REUTERS
·
Aug 24

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

THOMSON REUTERS
·
Aug 24

United Therapeutics Corporation - FDA Sets Pdufa Target Action Date for Ralinepag on June 24, 2027

THOMSON REUTERS
·
Aug 24

United Therapeutics Chairperson, CEO Martine Rothblatt Disposes of 9,500 Common Shares for $5.01 Million

Reuters
·
Aug 21

United Therapeutics CEO Martine Rothblatt Disposes of 9,500 Shares for $4.79 Million

Reuters
·
Aug 19

United Therapeutics announces full enrollment in TETON-PPF study

TIPRANKS
·
Aug 17

United Therapeutics Seeks FDA Priority Review for Tyvaso Label Expansion in IPF

Reuters
·
Aug 17

United Therapeutics Corporation Announces Full Enrollment of the Teton-Ppf Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

THOMSON REUTERS
·
Aug 17

United Therapeutics Corporation - Topline Data from Teton-Ppf Study Expected in Second Half of 2027

THOMSON REUTERS
·
Aug 17

United Therapeutics CEO Chair Martine Rothblatt Disposes of 9,500 Shares for $4.81 Million

Reuters
·
Aug 15

United Therapeutics Chairperson and CEO Martine Rothblatt Disposes of 8,500 Common Shares Worth $4.45 Million

Reuters
·
Aug 13

United Therapeutics CEO Chairperson Martine Rothblatt Disposes of 9,500 Shares Worth $5.03 Million

Reuters
·
Aug 11

aTyr Pharma Q2 Net Loss Narrows

Reuters
·
Aug 08

Inogen Q2 Revenue up Driven by Higher Demand for Portable Oxygen Concentrators

Reuters
·
Aug 07

United Therapeutics CEO Martine Rothblatt Disposes of 9,595 Common Shares Worth $4.98 Million

Reuters
·
Aug 07

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

TIPRANKS
·
Aug 07

United Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 07